Table 3.
Multivariable time-varying Cox regression for effect of ICI-T1DM on overall survival
| HR (95% CI) | P | |
|---|---|---|
| T1DM | 1.14 (0.95, 1.37) | 0.16 |
| Age (unit = 5 years) | 1.07 (1.06, 1.08) | <0.0001 |
| ICI types | ||
| Anti–PD-1/PD-L1 | Reference | |
| Anti–CTLA-4 | 0.73 (0.49, 1.08) | 0.11 |
| Anti–PD-1/PD-L1 + anti–CTLA-4 | 0.89 (0.84, 0.95) | 0.0003 |
| Tumor type | ||
| Melanoma | Reference | |
| Lung | 1.70 (1.59, 1.81) | <0.0001 |
| Both | 1.70 (1.55, 1.87) | <0.0001 |
| Other | 1.81 (1.70, 1.93) | <0.0001 |
| Sex | ||
| Male | Reference | |
| Female | 0.89 (0.86, 0.92) | <0.0001 |
| Race | ||
| White | Reference | |
| Black | 0.99 (0.94, 1.07) | 0.64 |
| Asian | 0.98 (0.88, 1.09) | 0.69 |
| Hispanic | 0.94 (0.88, 1.01) | 0.07 |
| Weighted CMI | ||
| <5 | Reference | |
| ≥5 | 1.53 (1.36, 1.73) | <0.0001 |
| Diabetes before ICI | ||
| No | Reference | |
| Yes | 1.12 (1.08, 1.16) | <0.0001 |
| Smoking | ||
| No | Reference | |
| Yes | 1.13 (1.08, 1.18) | <0.0001 |
| Immunosuppressant† | ||
| No | Reference | |
| Low-dose glucocorticoids | 1.21 (1.15, 1.27) | <0.0001 |
| Immunosuppressive drugs | 1.63 (1.55, 1.72) | <0.0001 |
†
Use of immunosuppressant medication within 3 months prior to the start of ICI.